NCCN Pfizer Investigator-Sponsored Research Project to Evaluate the Effectiveness of Elranatamab in the Treatment of Multiple Myeloma

Organization
NCCN, Pfizer
Type
Foundation
Application Due Date
08-02-2023
Brief Description

The National Comprehensive Cancer Network® (NCCN) and Pfizer Global Medical Grants are collaborating to offer a new grant opportunity seeking proposals for investigator-sponsored research with elranatamab. Pfizer (hereafter, “Grantor”) is providing up to $5 Million Dollars in research grants to support clinical research studies to further evaluate the effectiveness of elranatamab in the treatment of Multiple Myeloma. The Grantor will serve as the funding organization. Grants are available to all investigators from institutions within the United States.